Calendar An icon of a desk calendar. Cancel An icon of a circle with a diagonal line across. Caret An icon of a block arrow pointing to the right. Email An icon of a paper envelope. Facebook An icon of the Facebook "f" mark. Google An icon of the Google "G" mark. Linked In An icon of the Linked In "in" mark. Logout An icon representing logout. Profile An icon that resembles human head and shoulders. Telephone An icon of a traditional telephone receiver. Tick An icon of a tick mark. Is Public An icon of a human eye and eyelashes. Is Not Public An icon of a human eye and eyelashes with a diagonal line through it. Pause Icon A two-lined pause icon for stopping interactions. Quote Mark A opening quote mark. Quote Mark A closing quote mark. Arrow An icon of an arrow. Folder An icon of a paper folder. Breaking An icon of an exclamation mark on a circular background. Camera An icon of a digital camera. Caret An icon of a caret arrow. Clock An icon of a clock face. Close An icon of the an X shape. Close Icon An icon used to represent where to interact to collapse or dismiss a component Comment An icon of a speech bubble. Comments An icon of a speech bubble, denoting user comments. Comments An icon of a speech bubble, denoting user comments. Ellipsis An icon of 3 horizontal dots. Envelope An icon of a paper envelope. Facebook An icon of a facebook f logo. Camera An icon of a digital camera. Home An icon of a house. Instagram An icon of the Instagram logo. LinkedIn An icon of the LinkedIn logo. Magnifying Glass An icon of a magnifying glass. Search Icon A magnifying glass icon that is used to represent the function of searching. Menu An icon of 3 horizontal lines. Hamburger Menu Icon An icon used to represent a collapsed menu. Next An icon of an arrow pointing to the right. Notice An explanation mark centred inside a circle. Previous An icon of an arrow pointing to the left. Rating An icon of a star. Tag An icon of a tag. Twitter An icon of the Twitter logo. Video Camera An icon of a video camera shape. Speech Bubble Icon A icon displaying a speech bubble WhatsApp An icon of the WhatsApp logo. Information An icon of an information logo. Plus A mathematical 'plus' symbol. Duration An icon indicating Time. Success Tick An icon of a green tick. Success Tick Timeout An icon of a greyed out success tick. Loading Spinner An icon of a loading spinner. Facebook Messenger An icon of the facebook messenger app logo. Facebook An icon of a facebook f logo. Facebook Messenger An icon of the Twitter app logo. LinkedIn An icon of the LinkedIn logo. WhatsApp Messenger An icon of the Whatsapp messenger app logo. Email An icon of an mail envelope. Copy link A decentered black square over a white square.

Top doctor slams ‘absolute rubbish’ Tayside cancer recurrence claim amid growing calls for answers

Breast x-rays are checked for abnormalities.
Breast x-rays are checked for abnormalities.

A top UK oncologist has rubbished claims breast cancer patients in Tayside were put at a 1-2% increased risk of having the disease return as a result of receiving lower doses of a chemotherapy drug.

Dr Greg Wilson, a leading specialist at the Christie Hospital in Manchester, one of the largest cancer treatment centres of its type anywhere Europe, said it was “perfectly reasonable” for consultants to reduce doses in the best interests of their patients.

More than 300 women and their families were told they may have been given lower than standard amounts of the treatment by doctors in Tayside between December 2016 and March 2019 in a bid to reduce harmful side effects.

It has since emerged fewer than 200 individuals were actually affected. A risk assessment commissioned by Scotland’s chief medical officer last month advised that between 1-2% of the patients, around one more each year, may see their cancer return.

However, Dr Wilson dismissed as “absolute rubbish” any suggestion the increased risk figure could apply to a general patient population, many of whom he said would not be able to tolerate a 100mg/m2 dose of docetaxel due to the side effects.

The specialist argued “a lot” of patients find a higher dose too toxic and as a result “most oncologists will look at their patients, whether they are not very fit, older or overweight, and will often reduce the dose”.

He said he knows many clinicians who lower the dose “as a matter of course” but do not have a written guideline to enforce it.

“You can only give as much chemotherapy as the patient will tolerate, since otherwise they will never complete the chemotherapy programme, which would be more detrimental,” Dr Wilson said.

“Docetaxel is only one of a number of chemotherapy drugs given in the protocol. Given the other drugs and treatments involved, I personally do not believe that using a reduced dose would increase the recurrence rate by 1%.”

Patients and families in Tayside have repeatedly called on senior figures to back up the 1-2% recurrence claim with data, or to release their methodology.

Dr David Dunlop, who chaired the group behind the risk assessment, has admitted the figure was not based on specific evidence but rather “on the expert judgement of leading cancer specialists based on clinical experience built up over many years”.

The finding remains at odds with the views of oncologists in Tayside and has been the subject of some scepticism from other top medical figures.

Dr Wilson said: “Giving the patient too much toxicity leads to them quitting treatment too early, which one could argue is more dangerous.

“I don’t think reducing to 80mg/m2 is going to make a significant difference for any individual patient when you are doing it for safety.”

Officials from the Royal College of Physicians arrived in Tayside last week to further investigate the practices of the local oncology team, and separate reviews into the deaths of 14 patients and wider implications of the revelations are ongoing.

A Scottish Government spokesperson said: “We are committed to ensuring patients get the best care and treatment possible.

“Which is why, following concerns about variations in treatment compared with other health boards in Scotland, we commissioned Healthcare Improvement Scotland (HIS) to carry out a review of breast cancer treatment in NHS Tayside.

“As a result of the resulting HIS report, the oncologists concerned accepted all recommendations and agreed to change practices to bring them in line with other health boards.”